单中心B型主动脉壁内血肿治疗经验
回顾性分析2015年2月至2021年2月单中心195例B型主动脉壁内血肿患者,115例接受最佳药物治疗(BMT),80例接受介入治疗(INT)。两组早中期全因死亡无显著差异,INT组溃疡样突起(ULP)风险显著降低,但存在手术相关并发症风险。
要点
- BMT组与INT组早期全因死亡(1.7% vs 2.5%,P=1.00)及中期全因死亡(8.3% vs 5.2%,P=.42)无显著差异。
- INT组新发ULP(4.3% vs 26.9%)、ULP增大(6.4% vs 31.3%)及高危ULP比例(10.9% vs 45.6%)均显著低于BMT组(P<.05)。
- INT组存在支架诱导新破口及内漏等手术相关并发症风险,BMT患者应密切监测ULP进展。
核心结论
- 基于有限经验,B型主动脉壁内血肿患者接受BMT或INT的中期临床结局相似。
- 接受INT的患者ULP风险可能降低,但手术相关事件风险更高;接受BMT的患者应密切监测ULP进展。
研究设计与样本
- 单中心回顾性研究,纳入2015年2月至2021年2月共195例连续B型主动脉壁内血肿患者。
- 115例接受最佳药物治疗(BMT),80例接受介入治疗(INT)。
- 主要终点为死亡率,次要终点包括临床和影像学结局。
主要发现
- BMT组与INT组早期全因死亡(1.7% vs 2.5%,P=1.00)和中期全因死亡(8.3% vs 5.2%,P=.42)无显著差异。
- INT组新发ULP(4.3% vs 26.9%,P<.05)、ULP增大(6.4% vs 31.3%,P<.05)及高危ULP比例(10.9% vs 45.6%,P<.05)均低于BMT组。
- 两组IMH消退发生率无显著差异,但INT组降主动脉最大直径大于BMT组。
- INT组存在支架诱导新破口和内漏等手术相关并发症风险。
临床怎么用
- 作者认为,B型主动脉壁内血肿患者接受BMT或INT的中期临床结局相似。
- 作者指出,接受INT的患者ULP风险可能降低,但手术相关事件风险更高。
- 作者建议,接受BMT的患者应密切监测ULP进展。
局限性
- 原文自述基于有限经验(Based on our limited experience)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The outcomes of the best medical treatment (BMT) and intervention treatment (INT) in a single-center experience were reported in type B intramural hematoma (IMH). METHODS: From February 2015 to February 2021, a total of 195 consecutive patients with type B IMH were enrolled in the study. The primary end point was mortality, and the secondary end points included clinical and imaging outcomes. The clinical outcomes were aortic-related death, retrograde type A aortic dissection, stent graft-induced new entry tear, endoleak, and reintervention. The imaging outcome was evaluated through the latest follow-up computed tomography angiography, which included aortic rupture, aortic dissection, aortic aneurysm, rapid growth of aortic diameter, newly developed or enlarged penetrating aortic ulcer or ulcer-like projection (ULP) and increased aortic wall thickness. Kaplan-Meier curves were used to assess the association between different treatments. RESULTS: Among the enrolled patients, 115 received BMT, and 80 received INT. There was no significant difference in early (1.7% vs 2.5%; P = 1.00) and midterm all-cause death (8.3% vs 5.2%; P = .42) between the BMT and INT groups. However, patients who underwent INT were at risk of procedure-related complications such as stent graft-induced new entry tear and endoleaks. The INT group was associated with a profound decrease in the risk of ULP, including newly developed ULP (4.3% vs 26.9%; P < .05), ULP enlargement (6.4% vs 31.3%; P < .05), and a lower proportion of high-risk ULP (10.9% vs 45.6%; P < .05). Although there was no significant difference in the incidence of IMH regression between the two groups, the maximum diameter of the descending aorta in patients receiving INT was larger compared with those treated with BMT. CONCLUSIONS: Based on our limited experience, patients with type B IMH treated with BMT or INT shared similar midterm clinical outcome. Patients who underwent INT may have a decreased risk of ULPs, but a higher risk of procedure-related events and patients on BMT should be closely monitored for ULP progression.
引用
- Hu X, Yang F, Liu J, et al. A single-center experience of type B aortic intramural hematoma. J Vasc Surg. 2023. PMID: 38941265. doi:10.1016/j.jvs.2023.10.044
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。